Education
About Us
Working with TipRanks
Follow Us
Cencora, Inc. (GB:0HF3)
:0HF3
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
3.82Last Year’s EPS
3.34Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: -4.59%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Positive
Cencora showcased strong financial performance with significant revenue and EPS growth, and raised guidance due to the success of its U.S. Healthcare Solutions segment and effective cost management. However, challenges in the international segment and increased interest expenses slightly offset these positive outcomes.Company Guidance
During Cencora's fiscal 2025 second quarter earnings call, the company announced a strong financial performance with revenue growth of 10% and adjusted diluted EPS growth of 16%. As a result, Cencora raised its full-year guidance for adjusted operating income and adjusted diluted EPS, with EPS now expected to be in the range of $15.70 to $15.95, representing growth of 14% to 16%. The U.S. Healthcare Solutions segment was a significant contributor, showing a 23% increase in operating income, driven by strong utilization trends and growth in specialty products. The company also highlighted the successful integration of Retina Consultants of America and the expansion of its specialty medication offerings across geographies. International Healthcare Solutions' performance was impacted by a subdued clinical trial activity, leading to a slight downward revision in its revenue growth outlook. Overall, Cencora remains focused on leveraging its expertise, deepening customer partnerships, and expanding its global leadership in specialty medications to drive continued growth.Strong Revenue and EPS Growth
Cencora reported a 10% increase in revenue and a 16% increase in adjusted diluted EPS for the second quarter of fiscal 2025.
Raised Guidance
Cencora raised its full-year guidance for adjusted operating income and adjusted diluted EPS due to strong U.S. Healthcare Solutions earnings performance and expectations for continued growth.
U.S. Healthcare Solutions Success
The U.S. Healthcare Solutions segment saw revenue grow by 11%, driven by strong utilization trends and growth in specialty products.
Effective Cost Management
Excluding RCA, Cencora maintained modest operating expense growth while focusing on productivity initiatives.
Successful Integrations and Strategic Investments
Cencora successfully integrated its U.S. and European 3PL businesses and continues to invest in capabilities and talent across its operations.
---
GB:0HF3 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:0HF3 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $292.21 | $304.76 | +4.29% |
Feb 05, 2025 | $252.79 | $253.37 | +0.23% |
Nov 06, 2024 | $235.44 | $245.89 | +4.44% |
Jul 31, 2024 | $230.31 | $235.19 | +2.12% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cencora, Inc. (GB:0HF3) report earnings?
Cencora, Inc. (GB:0HF3) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is Cencora, Inc. (GB:0HF3) earnings time?
Cencora, Inc. (GB:0HF3) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Cencora, Inc. stock?
The P/E ratio of Cencora is N/A.
What is GB:0HF3 EPS forecast?
GB:0HF3 EPS forecast for the fiscal quarter 2025 (Q3) is 3.82.
---